---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008009"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:51:00.806413+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics Q4/FY2022: Loss per share $1.73, cash $26.4M; Phase 1 Decoy20 trial underway

## Summary
- R&D expense $1.9M in Q4 (up 90% YoY); FY R&D $6.3M (up 150% YoY).
- Cash and marketable securities $26.4M as of Dec 31, 2022; runway into Q2 2024.
- First patient dosed in Phase 1 Decoy20 trial for solid tumors in March 2023; three sites activated.
- Net cash used in operations $13.1M for FY2022 vs $11.3M in FY2021.
- Robert Martell, M.D., Ph.D. elected to Board in February 2023.

## SEC filing metadata
- accession: 0001493152-23-008009
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223008009/0001493152-23-008009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223008009/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008009
- JSON: https://secwatch.observer/filing/0001493152-23-008009.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008009.txt

## Key facts
- Earnings Releases
  Indaptus Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 17, 2023, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315223008009/0001493152-23-008009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.